,59 Here, we detected, in blood, T cell responses against a broad range of MHC class I and class II tumor epitopes, suggesting the ability of UCPVax to enhance both CD4+ and CD8+ T cell diversification in vaccinated patients. This evidence concerns the gene CD8A and neoplasm.